3-methyl-1-(methylsulfonyl)-1H-indazole | 1376603-11-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 英文名称: 3-methyl-1-(methylsulfonyl)-1H-indazole
• 英文别名: 3-Methyl-1-methylsulfonylindazole
• CAS: 1376603-11-0
• 化学式: C₉H₁₀N₂O₂S
• 分子量: 210.257
• InChiKey: ISGQSOMQWTYIKA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  60.3
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  在 copper(II) acetate monohydrate 作用下， 以 甲苯 为溶剂， 110.0 ℃ 、101.33 kPa 条件下， 反应 4.0h， 以85%的产率得到3-methyl-1-(methylsulfonyl)-1H-indazole
  参考文献：
  名称：

  E / Z-邻卤代芳基N-磺酰基hydr的铜催化异构化和环化：便捷地获得1H-吲唑

  摘要：

  中C = N双键的异构化已经引起了广泛的关注，因为它具有广泛的化学转化应用潜力。通常，该异构化可以通过光化学或热方法实现。提出了一种新的异构化方法，即的铜催化的C = N双键异构化，然后进行有效的分子内C-N偶联反应，为从易于获得的1 H-吲唑合成提供了前所未有的催化方法邻卤代芳基N磺酰基hydr的Z / E混合物。

  DOI：

  10.1002/cctc.201601243

文献信息

• Copper(I) Oxide-Mediated Cyclization of<i>o</i>-Haloaryl<i>N</i>-Tosylhydrazones: Efficient Synthesis of Indazoles
  作者：Meng Tang、Yuanfang Kong、Bingjie Chu、Dan Feng

  DOI：10.1002/adsc.201500953

  日期：2016.3.17

  An efficient synthesis of indazoles from readily accessible E/Z mixtures of o‐haloaryl N‐tosylhydrazones has been developed. The thermo‐induced isomerization of N‐tosylhydrazones is discussed. A series of valuable indazole derivatives are prepared in good yields, and the method has been successfully applied to the synthesis of the bioactive compounds, lonidamine, AF‐2785, axitinib, YC‐1 and YD‐3.

  从邻卤代芳基N-甲苯磺酰基hydr的易获得的E / Z混合物中开发了吲唑的有效合成方法。讨论了N-甲苯磺酰hydr的热诱导异构化。以高收率制备了一系列有价值的吲唑衍生物，该方法已成功地用于生物活性化合物的合成，如：lonidamine，AF-2785，axitinib，YC-1和YD-3。
• INDAZOLE DERIVATIVES AND USES THEREOF
  申请人：Whitehead Institute for Bio-Medical Research

  公开号：US20150353503A1

  公开（公告）日：2015-12-10

  The present invention provides novel compounds (e.g., compounds of Formula (I)), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits comprising the inventive compounds, or compositions thereof, for treating and/or preventing a fungal or protozoan infection, inhibiting the activity of a fungal or protozoan enzyme, killing a fungus or protozoon, or inhibiting the growth of a fungus or protozoon. The fungus may be a Candida species, Aspergillus species, or other pathogenic fungal species. The compounds of the invention may inhibit the activity of fungal or protozoan cytochrome b and/or fungal or protozoan Hsp90. The present invention also provides synthetic methods of the inventive compounds.

  本发明提供了新型化合物（例如，公式（I）化合物），以及其药学上可接受的盐、溶剂合物、水合物、多晶形、共晶体、互变异构体、立体异构体、同位素标记衍生物、前药和组合物。还提供了包含本发明化合物或其组合物的方法和试剂盒，用于治疗和/或预防真菌或原虫感染、抑制真菌或原虫酶的活性、杀灭真菌或原虫或抑制真菌或原虫的生长。真菌可能是念珠菌属、曲霉属或其他致病真菌种类。本发明化合物可以抑制真菌或原虫细胞色素b和/或真菌或原虫Hsp90的活性。本发明还提供了本发明化合物的合成方法。
• PYRIMIDINE OR PYRIDINE COMPOUNDS, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USES THEREOF
  申请人：Shanghai Shaletech Technology Co., Ltd.

  公开号：EP3216786A1

  公开（公告）日：2017-09-13

  The present invention disclosed a class of pyrimidine or pyridine compounds, pharmaceutically acceptable salts, stereoisomers, prodrugs and solvates thereof, preparation method therefor and pharmaceutical compositions and pharmaceutical uses thereof. The compounds can inhibit the variants of EGFR (Epidermis Growth Factor Receptor) proteinases, and therefore can inhibit the growth of a variety of tumor cells effectively. The compounds can be used to prepare antitumor drugs, used for the treatment, combined therapy or prevention of various different cancers. The compounds can overcome the drug resistance induced by the existing first-generation EGFR inhibitors such as gefitinib, erlotinib and so on. Particularly, the compounds can be used to prepare drugs for treating or preventing diseases, disturbances, disorders or conditions mediated by epidermis growth factor receptor variants (such as L858R activated mutants, Exon19 deletion activated mutants and T790M resistant mutants).

  本发明公开了一类嘧啶或吡啶化合物、其药学上可接受的盐、立体异构体、原药和溶液、其制备方法和药物组合物及其药物用途。这些化合物可以抑制表皮生长因子受体蛋白酶的变体，从而有效抑制多种肿瘤细胞的生长。这些化合物可用于制备抗肿瘤药物，用于治疗、联合治疗或预防各种不同的癌症。这些化合物可以克服现有的第一代表皮生长因子受体抑制剂（如吉非替尼、厄洛替尼等）引起的耐药性。特别是，这些化合物可用于制备治疗或预防由表皮生长因子受体变体（如 L858R 激活突变体、Exon19 缺失激活突变体和 T790M 耐药突变体）介导的疾病、紊乱、失调或病症的药物。
• PYRIMIDINE COMPOUNDS, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USES THEREOF
  申请人：InventisBio Co., Ltd.

  公开号：EP3885344A2

  公开（公告）日：2021-09-29

  The present invention disclosed a class of pyrimidine or pyridine compounds, pharmaceutically acceptable salts, stereoisomers, prodrugs and solvates thereof, preparation method therefor and pharmaceutical compositions and pharmaceutical uses thereof. The compounds can inhibit the variants of EGFR (Epidermis Growth Factor Receptor) proteinases, and therefore can inhibit the growth of a variety of tumor cells effectively. The compounds can be used to prepare antitumor drugs, used for the treatment, combined therapy or prevention of various different cancers. The compounds can overcome the drug resistance induced by the existing first-generation EGFR inhibitors such as gefitinib, erlotinib and so on. Particularly, the compounds can be used to prepare drugs for treating or preventing diseases, disturbances, disorders or conditions mediated by epidermis growth factor receptor variants (such as L858R activated mutants, Exon19 deletion activated mutants and T790M resistant mutants).

  本发明公开了一类嘧啶或吡啶化合物、其药学上可接受的盐、立体异构体、原药和溶液、其制备方法和药物组合物及其药物用途。这些化合物可以抑制表皮生长因子受体蛋白酶的变体，从而有效抑制多种肿瘤细胞的生长。这些化合物可用于制备抗肿瘤药物，用于治疗、联合治疗或预防各种不同的癌症。这些化合物可以克服现有的第一代表皮生长因子受体抑制剂（如吉非替尼、厄洛替尼等）引起的耐药性。特别是，这些化合物可用于制备治疗或预防由表皮生长因子受体变体（如 L858R 激活突变体、Exon19 缺失激活突变体和 T790M 耐药突变体）介导的疾病、紊乱、失调或病症的药物。
• Synthesis, structure of the N-(Alkyl/Arylsulfonyl) substituted 5-(Bromo/Iodo)-3-methylindazoles and bioactivity screening against some of the biochemical targets linked to type 2 diabetes mellitus
  作者：Malose J. Mphahlele、Nontokozo M. Magwaza、Garland K. More、Ahmed A. Elhenawy

  DOI：10.1016/j.molstruc.2024.138636

  日期：2024.9

  moiety have evoked high interest in medicinal chemistry especially in the context of antidiabetic drug development. A series of the C-5 unsubstituted (2a–f), 5‑bromo (2g–l) and 5-iodo (2m–r) substituted 1-(alkyl/arylsulfonyl)-3-methylindazoles were prepared, characterized and then evaluated through enzymatic assay in vitro for anti-α-glucosidase activity and for potential free radical scavenging properties

  吲唑支架和磺酰胺部分引起了人们对药物化学的高度兴趣，特别是在抗糖尿病药物开发的背景下。制备、表征并评估了一系列 C-5 未取代 (2a–f)、5-溴 (2g–l) 和 5-碘 (2m–r) 取代的 1-(烷基/芳基磺酰基)-3-甲基吲唑通过体外酶法测定抗α-葡萄糖苷酶活性和潜在的自由基清除特性。与阿卡波糖相比，化合物 2b、2d、2f–h、2k、2p 和 2q 对 α-葡萄糖苷酶表现出更强的活性 (IC50 = 1.30 ± 0.02 µM)，IC50 值在 0.72 ± 0.03 – 1.20 ± 0.01 µM 范围内。这些化合物表现出增强或强的 2,2-二苯基-1-三硝基苯肼 (DPPH) 和/或一氧化氮 (NO) 自由基清除活性。反过来，通过体外酶测定评估这些化合物抑制或激活超氧化物歧化酶 (SOD)、脂氧合酶 15 (LOX-15) 和/或血管内皮生长因子受体 2 (VEGFR-2)